A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies-Reference-Cited by-同舟云学术

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

Published:2013-11-14 Issue:20 Volume:122 Page:3500-3510
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Deckert Jutta¹,Park Peter U.¹,Chicklas Sharon¹,Yi Yong¹,Li Min¹,Lai Katharine C.²,Mayo Michele F.³,Carrigan Christina N.⁴,Erickson Hans K.²,Pinkas Jan³,Lutz Robert J.⁵,Chittenden Thomas⁵,Lambert John M.⁵

Affiliation:

1. Discovery Research,

2. Biochemistry,

3. Pharmacology and Toxicology,

4. Immunohistochemistry, and

5. Research and Development, ImmunoGen, Inc., Waltham, MA

Abstract

Key Points An anti-CD37 antibody-drug conjugate can kill B-lymphoma cells via direct inhibition, effector function, and payload delivery. Targeting CD37 with an antibody-drug conjugate results in selective depletion of malignant human B cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/20/3500/1371907/3500.pdf

Reference49 articles.

1. A unique antigen on mature B cells defined by a monoclonal antibody.;Link;J Immunol,1986

2. The tetraspanin superfamily: molecular facilitators.;Maecker;FASEB J,1997

3. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein.;Schwartz-Albiez;J Immunol,1988

4. A regulatory role for CD37 in T cell proliferation.;van Spriel;J Immunol,2004

5. Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions.;Knobeloch;Mol Cell Biol,2000

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Tetraspanin proteins in membrane remodeling processes;Journal of Cell Science;2024-07-15

3. Comprehensive Analysis of¹⁷⁷Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes;2024-06-03

4. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia;Cell Reports Medicine;2024-06

5. Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies;Cancers;2023-12-08